We have previously demonstrated that inhibition of PP2A, through mutation or siRNA-mediated knockdown of PP2A-Aα, contributes to MEK1/2 inhibitor resistance in KRAS-mutant colon and lung cancers (23, 28). Here, PTPA is linked to lung cancer.